Page 2 - Microenvironment Metastasis Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Credit: The Wistar Institute PHILADELPHIA -- (April 1, 2021 -- Scientists at The Wistar Institute identified a new mechanism of transcriptional control of cellular senescence that drives the release of inflammatory molecules that influence tumor development through altering the surrounding microenvironment. The study, published in Nature Cell Biology, reports that methyltransferase-like 3 (METTL3) and 14 (METTL14) proteins moonlight as transcriptional regulators that allow for establishment of the senescence-associated secretory phenotype (SASP). Cellular senescence is a stable state of gro...

(1) BEDMINSTER, N.J., Jan. 15, 2021 /PRNewswire/ -- Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced a collaboration with The Wistar Institute, an international leader in biomedical research, to evaluate the ability of Peptidyl Arginine Deiminase 4 (PAD4) inhibitors provided by Jubilant Therapeutics to block neutrophil extracellular trap (NET) formation in the context of COVID-19 related cytokine storms. PAD4 is an enzyme that catalyzes conversion of arginine to cit...

Researchers Identify Link Between Ovarian Cancer, Metabolism by Angela Mohan on  January 12, 2021 at 5:24 PM Nature Cancer. Up to 60% of ovarian clear cell carcinomas (OCCC) have inactivating mutations in the ARID1A tumor suppressor gene. These mutations are known genetic drivers of this type of cancer, which typically does not respond to chemotherapy and carries the worst prognosis among all subtypes of ovarian cancer. The laboratory of Rugang Zhang, Ph.D., deputy director of The Wistar Institute Cancer Center, professor and leader of the Immunology, Microenvironment & Met...

Link between driver of ovarian cancer, metabolism opens up new therapeutic strategies ANI | Updated: Jan 12, 2021 11:45 IST Washington [US], January 12 (ANI): Mutations that inactivate the ARID1A gene in ovarian cancer increase utilisation of the glutamine amino acid making cancer cells dependent on glutamine metabolism, according to a study by The Wistar Institute published online in Nature Cancer. Researchers also showed that pharmacologic inhibition of glutamine metabolism may represent an effective therapeutic strategy for ARID1A-mutant ovarian cancer...